The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study

Author: Eby Elizabeth L.   Boye Kristina S.   Lage Maureen J.  

Publisher: Informa Healthcare

ISSN: 1369-6998

Source: Journal of Medical Economics, Vol.16, Iss.10, 2013-10, pp. : 1231-1237

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Abstract Objective:To compare all-cause and diabetes-related resource utilization and healthcare charges among adults with type 2 diabetes mellitus who initiated therapy with mealtime insulin disposable pens or vials. Methods:Data were obtained from the Innovus inVision™ database from January 1, 2006 through June 30, 2010. Generalized linear models with a gamma distribution and log link estimated the association between medical charges and use of mealtime insulin pens vs vials in the 1 year post-index date, while generalized linear models with a negative binomial distribution estimated resource utilization. Results:Controlling for patient characteristics, general health, and patient copayments, insulin therapy initiation with disposable pens, compared to vials, was associated with significantly fewer all-cause hospitalizations (1.45 vs 1.66; p < 0.0001) as well as a significantly shorter hospital length of stay (2.16 days vs 3.53 days; p < 0.0001). Pen use, compared to vials, was also associated with significantly fewer diabetes-related hospitalizations (1.36 vs 1.47; p < 0.0001), and shorter hospital length of stay (1.12 days vs 1.72 days; p < 0.0001). Despite higher diabetes-related drug charges ($3593 vs $2755; p < 0.0001) associated with the use of pens, results showed significantly lower all-cause total healthcare charges ($42,150 vs $53,340; p < 0.0001) and significantly lower diabetes-related total healthcare charges ($12,722 vs $14,540; p < 0.0001) for patients who initiated therapy on mealtime insulin with pens compared to vials. Limitations:Data were drawn from administrative claims and included only patients with medical and outpatient prescription drug benefit coverage. Hence, the results may not be generalizable. The retrospective analyses relied on diagnostic codes to identify patients, assess patient general health, and determine other values, rather than formal, clinical assessments. The analyses did not include indirect healthcare costs. Conclusions:The administration of mealtime insulin via disposable pens, compared to vials, was associated with a significant reduction in all-cause and diabetes-related resource utilization and total healthcare charges.

Related content